NCT05299359View on ClinicalTrials.gov

A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

June 11, 2022

Study Completion Date

October 18, 2023

Conditions
Coronavirus Disease (COVID-19)
Interventions
BIOLOGICAL

TAK-019

TAK-019 intramuscular injection

Trial Locations (2)

Unknown

Sumida Hospital, Sumida-ku

PS Clinic, Fukuoka

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05299359 - A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19) | Biotech Hunter | Biotech Hunter